FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2298802783> ?p ?o ?g. }

• W2298802783 abstract "We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual lesions, however, was not reported. Since talimogene laherparepvec is thought to mediate anti-tumor activity through both direct tumor cytolysis and induction of systemic tumor-specific immunity, we sought to determine the independent response rate in virus-injected and non-injected lesions.Fifty patients with stage IIIC or IV melanoma were treated with talimogene laherparepvec in a multi-institutional single-arm open-label phase II clinical trial. In this study patients were treated until a complete response was achieved, all accessible tumors disappeared, clinically significant disease progression, or unacceptable toxicity. This report is a post hoc analysis of the systemic effects of talimogene laherparepvec in injected lesions and two types of uninjected lesions-non-visceral lesions and visceral lesions.Eleven of 23 patients (47.8 %) had a ≥ 30 % reduction in the total burden of uninjected non-visceral lesions, and 2 of 12 patients (16.7 %) had a ≥ 30 % reduction in the total burden of visceral lesions. Among 128 evaluable lesions directly injected with talimogene laherparepvec, 86 (67.2 %) decreased in size by ≥ 30 % and 59 (46.1 %) completely resolved. Of 146 uninjected non-visceral lesions, 60 (41.1 %) decreased in size by ≥ 30 %, the majority of which (44 [30.1 %]) completely resolved. Of 32 visceral lesions, 4 (12.5 %) decreased in size by ≥ 30 %, and 3 (9.4 %) completely resolved. The median time to lesion response was shortest for lesions that were directly injected (18.4 weeks), followed by uninjected non-visceral lesions (23.1 weeks) and visceral lesions (51.3 weeks), consistent with initiation of a delayed regional and systemic anti-tumor immune response to talimogene laherparepvec.These results support a regional and systemic effect of talimogene laherparepvec immunotherapy in patients with advanced melanoma." @default.
• W2298802783 created "2016-06-24" @default.
• W2298802783 creator A5002655892 @default.
• W2298802783 creator A5006404846 @default.
• W2298802783 creator A5011662854 @default.
• W2298802783 creator A5030466764 @default.
• W2298802783 creator A5046995957 @default.
• W2298802783 creator A5052584121 @default.
• W2298802783 creator A5055054082 @default.
• W2298802783 creator A5072284989 @default.
• W2298802783 creator A5075350327 @default.
• W2298802783 creator A5080006341 @default.
• W2298802783 creator A5090739964 @default.
• W2298802783 date "2016-03-15" @default.
• W2298802783 modified "2023-09-29" @default.
• W2298802783 title "Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study" @default.
• W2298802783 cites W1428163254 @default.
• W2298802783 cites W1551579334 @default.
• W2298802783 cites W1950572133 @default.
• W2298802783 cites W1968566356 @default.
• W2298802783 cites W1987657194 @default.
• W2298802783 cites W1990675339 @default.
• W2298802783 cites W2006521968 @default.
• W2298802783 cites W2010011171 @default.
• W2298802783 cites W2021115043 @default.
• W2298802783 cites W2030378290 @default.
• W2298802783 cites W2034135911 @default.
• W2298802783 cites W2050271506 @default.
• W2298802783 cites W2057577614 @default.
• W2298802783 cites W2063495860 @default.
• W2298802783 cites W2082150850 @default.
• W2298802783 cites W2086591619 @default.
• W2298802783 cites W2092752195 @default.
• W2298802783 cites W2097995306 @default.
• W2298802783 cites W2099648846 @default.
• W2298802783 cites W2102033291 @default.
• W2298802783 cites W2109274792 @default.
• W2298802783 cites W2112897941 @default.
• W2298802783 cites W2126821510 @default.
• W2298802783 cites W2127532535 @default.
• W2298802783 cites W2132411790 @default.
• W2298802783 cites W2137409431 @default.
• W2298802783 cites W2165320653 @default.
• W2298802783 cites W2170739773 @default.
• W2298802783 cites W2330814896 @default.
• W2298802783 cites W2561129352 @default.
• W2298802783 cites W2572174216 @default.
• W2298802783 cites W2599866288 @default.
• W2298802783 cites W4233697092 @default.
• W2298802783 doi "https://doi.org/10.1186/s40425-016-0116-2" @default.
• W2298802783 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4791835" @default.
• W2298802783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26981242" @default.
• W2298802783 hasPublicationYear "2016" @default.
• W2298802783 type Work @default.
• W2298802783 sameAs 2298802783 @default.
• W2298802783 citedByCount "76" @default.
• W2298802783 countsByYear W22988027832015 @default.
• W2298802783 countsByYear W22988027832016 @default.
• W2298802783 countsByYear W22988027832017 @default.
• W2298802783 countsByYear W22988027832018 @default.
• W2298802783 countsByYear W22988027832019 @default.
• W2298802783 countsByYear W22988027832020 @default.
• W2298802783 countsByYear W22988027832021 @default.
• W2298802783 countsByYear W22988027832022 @default.
• W2298802783 countsByYear W22988027832023 @default.
• W2298802783 crossrefType "journal-article" @default.
• W2298802783 hasAuthorship W2298802783A5002655892 @default.
• W2298802783 hasAuthorship W2298802783A5006404846 @default.
• W2298802783 hasAuthorship W2298802783A5011662854 @default.
• W2298802783 hasAuthorship W2298802783A5030466764 @default.
• W2298802783 hasAuthorship W2298802783A5046995957 @default.
• W2298802783 hasAuthorship W2298802783A5052584121 @default.
• W2298802783 hasAuthorship W2298802783A5055054082 @default.
• W2298802783 hasAuthorship W2298802783A5072284989 @default.
• W2298802783 hasAuthorship W2298802783A5075350327 @default.
• W2298802783 hasAuthorship W2298802783A5080006341 @default.
• W2298802783 hasAuthorship W2298802783A5090739964 @default.
• W2298802783 hasBestOaLocation W22988027831 @default.
• W2298802783 hasConcept C121608353 @default.
• W2298802783 hasConcept C126322002 @default.
• W2298802783 hasConcept C143998085 @default.
• W2298802783 hasConcept C2776694085 @default.
• W2298802783 hasConcept C2777658100 @default.
• W2298802783 hasConcept C2777701055 @default.
• W2298802783 hasConcept C3019096185 @default.
• W2298802783 hasConcept C502942594 @default.
• W2298802783 hasConcept C71924100 @default.
• W2298802783 hasConcept C82210918 @default.
• W2298802783 hasConceptScore W2298802783C121608353 @default.
• W2298802783 hasConceptScore W2298802783C126322002 @default.
• W2298802783 hasConceptScore W2298802783C143998085 @default.
• W2298802783 hasConceptScore W2298802783C2776694085 @default.
• W2298802783 hasConceptScore W2298802783C2777658100 @default.
• W2298802783 hasConceptScore W2298802783C2777701055 @default.
• W2298802783 hasConceptScore W2298802783C3019096185 @default.
• W2298802783 hasConceptScore W2298802783C502942594 @default.
• W2298802783 hasConceptScore W2298802783C71924100 @default.
• W2298802783 hasConceptScore W2298802783C82210918 @default.
• W2298802783 hasFunder F4320307105 @default.
• W2298802783 hasIssue "1" @default.

• next